New York, NY, Sept.20, 2007, Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, announced today that complete enrollment of its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer) was accomplished ahead…
NEW YORK, Aug. 29, 2007 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL – News; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, today announced that the staff of the American Stock Exchange (“AMEX”) has reviewed the Company’s plan of compliance to meet the AMEX’s continued…
New York, NY, Aug. 9, 2007, Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer). With the…
NEW YORK, August 8 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, is pleased to provide an update covering its strategic and drug development activities for the second quarter of 2007. “Callisto has made substantial progress with our clinical and…
NEW YORK, Aug. 7 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL – News; FWB: CA4), a biopharmaceutical company primarily focused on the development of new drugs to treat cancer and gastrointestinal diseases, announced today that it has closed a private placement of 1,124,550 shares of Series B Convertible Preferred Stock and 22,491,000 warrants for aggregate…
Multi-Institutional Trial Utilizes POETIC Consortium of Ten Institutions with First Patient Dosed at The Children’s Hospital, Denver CO. NEW YORK, March 8 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (AMEX: KAL), a developer of new drug treatments in the fight against cancer and other major health threats, announced today the dosing of a patient in a Phase…
NEW YORK, June 25 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today the addition of a clinical site to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid…
NEW YORK, June 8 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the development of new drugs to treat cancer and inflammatory diseases, announced today that it has filed a complaint against Donald Picker, its former Executive Vice President, Research & Development in the Supreme Court of the State…
NEW YORK, May 24 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drugs for the treatment of cancer and inflammatory diseases, announced today the addition of Lahey Clinic in Burlington, MA to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer)….
History of Atiprimod Appears in Genetic Engineering & Biotechnology News NEW YORK, May 15 /PRNewswire-FirstCall/ — Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the development of new drugs to treat cancer and inflammatory diseases, announced today that an article citing the history of its anti-cancer drug Atiprimod appeared in Genetic…